Letrozole-d4 |
Catalog No.GC47554
One-Click Copy Product Info
|
레트로졸-d4(CGS 20267-d4)는 레트로졸로 표시된 중수소입니다. 레트로졸(CGS 20267)은 11.5nM의 IC50을 갖는 아로마타제의 강력하고 선택적이고 가역적이며 경구 활성인 비스테로이드성 억제제입니다. 레트로졸 선택은 에스트로겐 생합성을 억제하고 유방암 연구에 사용될 수 있습니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1133712-96-5
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Letrozole-d4 is intended for use as an internal standard for the quantification of letrozole by GC- or LC-MS. Letrozole is a potent, cell-permeable inhibitor of aromatase (IC50 = 2 nM).1 It inhibits proliferation of estrogen receptor-positive (ER+) MCF-7 cells when used alone at concentrations ranging from 0.1 to 100 nM and when used at a concentration of 10 nM in combination with testosterone or 4-androstene-3,17-dione.2 It also reduces matrix metalloproteinase-2 (MMP-2) and MMP-9 levels in MCF-7 cells when used at a concentration of 10 nM. Letrozole (10 µg per day) reduces tumor growth in an MCF-7Ca ovariectomized-mouse xenograft model.3 Formulations containing letrozole have been used in the treatment of postmenopausal breast cancer.4
1.Mayhoub, A.S., Marler, L., Kondratyuk, T.P., et al.Optimization of the aromatase inhibitory activities of pyridylthiazole analogues of resveratrolBioorg. Med. Chem.20(7)2427-2434(2012) 2.Mitropoulou, T.N., Tzanakakis, G.N., Kletsas, D., et al.Letrozole as a potent inhibitor of cell proliferation and expression of metalloproteinases (MMP-2 and MMP-9) by human epithelial breast cancer cellsInt. J. Cancer104(2)155-160(2003) 3.Long, B.J., Jelovac, D., Handratta, V., et al.Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer modelJ. Natl. Cancer Inst.96(6)456-465(2004) 4.Cohen, M.H., Johnson, J.R., Li, N., et al.Approval summary: Letrozole in the treatment of postmenopausal women with advanced breast cancerClin Cancer Res.8(3)665-669(2002)
| Cas No. | 1133712-96-5 | SDF | |
| Canonical SMILES | [2H]C(C([2H])=C(C#N)C([2H])=C1[2H])=C1C(N2C=NC=N2)C3=CC=C(C#N)C=C3 | ||
| Formula | C17H7D4N5 | M.Wt | 289.3 |
| Solubility | DMF: 16 mg/ml,DMF:PBS (pH 7.2) (1:9): 0.1 mg/ml,DMSO: 16 mg/ml | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.4566 mL | 17.2831 mL | 34.5662 mL |
| 5 mM | 691.3 μL | 3.4566 mL | 6.9132 mL |
| 10 mM | 345.7 μL | 1.7283 mL | 3.4566 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 20 reference(s) in Google Scholar.)